Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133727 | 0.97 | DRD2 (0.49) | DRD2HTR6ALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6134453 | 0.80 | MAPT (0.53) | DRD2HTR6ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5937247 | 0.77 | ADRA1D (0.52) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL6135265 | 0.76 | DRD2 (0.49) | DRD2HTR6ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5705015 | 0.76 | DRD2 (0.49) | DRD2HTR6ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5240385 | 0.75 | SLC5A1 (0.52) | DRD2HTR6ALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6133263 | 0.74 | HTR6 (0.49) | HTR6ALDH1A1CYP1A2CYP3A4GAA | |
| SCHEMBL3598394 | 0.73 | SIGMAR1 (0.57) | DRD2HTR6GAA | |
| SCHEMBL6777121 | 0.73 | DRD2 (0.62) | DRD2HTR6 | |
| SCHEMBL3605157 | 0.73 | SLC2A1 (0.53) | DRD2HTR6ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | DRD2 2595/4885HTR6 1013/4885ALDH1A1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.